Gore Announces First-in-Human Use of GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System for TEVAR
New delivery system provides controlled and predictable placement of Gore’s highly conformable and time-tested stent graft
Gore Completes Patient Enrollment in U.S. Pivotal Clinical Study of GORE® CARDIOFORM ASD Occluder
New addition to GORE® CARDIOFORM Occluder family is designed to treat larger atrial septal defects by adapting to the patient’s anatomy for a permanent and safe closure
Celebrating the 20th Anniversary of the GORE® EXCLUDER® Device
With two decades of evolution and more than 300,000 patients treated* worldwide, this trusted, market-leading EVAR device continues to advance patient care
Gore Launches Anti-Migration Assurance Program for GORE® VIABIL® Short Wire Biliary Endoprosthesis
Device is proven to reduce the risk of reintervention for patients with pancreatic and other cancers that obstruct the bile duct; replacement program can help limit overall costs of palliative care
Gore Marks 20th Year on 100 Best Companies to Work For® List
Gore has appeared in every edition of the rankings, published annually in Fortune magazine. The company is among just 12 “Great Place to Work Legends” to hold this distinction.
First Patient Enrolled in European Post-Market Registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System
Real-world outcomes of TEVAR procedures performed with new delivery system that enables positioning and angulation control during stent graft deployment
Physicians Report Early Successes Across Multiple Applications in First-in-Human Uses of GORE® SYNECOR Preperitoneal Biomaterial Hernia Repair Device
New three-layer hybrid biomaterial, ideal for TAR procedures, offering permanent strength and rapid tissue generation for single-stage repairs